Mutations in IDH1 (isocitrate dehydrogenase), which are more common in low-grade astrocytic gliomas may be also present in GBM, which influence patient prognosis and response to treatment, where mutation in IDH1 give more favorable overall survival prognosis for patient compare to IDH wild type [6,9,15]. Here, IDH1 is linked to glioblastoma.